Mon panier

Biotinylated Human B7-H7 / HHLA2 Protein, Fc,Avitag™ (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
B77-H82F3-25ug
$360.00
B77-H82F3-200ug
$1420.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    B7-H7, HHLA2, B7 Homolog 7

  • Source

    Biotinylated Human B7-H7 Protein, Fc,Avitag (B77-H82F3) is expressed from human 293 cells (HEK293). It contains AA Ile 23 - Asn 344 (Accession # Q9UM44-1).

    Predicted N-terminus: Ile 23

    Request for sequence
  • Molecular Characterization

    B7-H7 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 65.1 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    B7-H7 SDS-PAGE

    Biotinylated Human B7-H7 Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    B7-H7 SEC-MALS

    The purity of Biotinylated Human B7-H7 Protein, Fc,Avitag (Cat. No. B77-H82F3) is more than 90% and the molecular weight of this protein is around 155-175 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     B7-H7 ELISA

    Immobilized Human CD28H, Fc Tag (Cat. No. CDH-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-H7 Protein, Fc,Avitag (Cat. No. B77-H82F3) with a linear range of 1-20 ng/mL (QC tested).

    Protocol
  •  B7-H7 ELISA

    Immobilized Human CD28H, His Tag (Cat. No. CDH-H52H3) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-H7 Protein, Fc,Avitag (Cat. No. B77-H82F3) with a linear range of 1-78 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

B7-H7 (HHLA2) is a newly identified B7 family member that regulates human T-cell functions. B7-H7 was previously known as human endogenous retrovirus-H long terminal repeat associating 2 (HHLA2) with unidentified function. Recently, B7-H7 has been identified as a specific ligand for human CD28H. The B7-H7-CD28H pathway strongly promoted CD4+ T-cell proliferation and cytokine production via an AKT-dependent signaling cascade in the presence of TCR signaling, suggesting B7-H7 comprises a new co-stimulatory pathway. The first IgV domain of B7-H7, which presumably binds to a putative receptor, shows the highest homology to other B7 family members.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    HERV-H LTR-associating protein 2

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    2 Détails

  • Étape de développement la plus élevée:

    Phase 1 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte